Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. Print this page
' ?) U; F+ C) e3 a0 j. E
8 I v2 x# R+ j8 \! [3 s$ n5 P* K0 @% ]. o4 P
Sub-category:
' e! m! m2 Z5 eMolecular Targets # ]* ?4 {- d. ?3 K. v
1 [# Y. {& @: |' y# r! O, w
& M# o9 Z* U4 h- b- e
Category:0 g4 `" L/ N( G/ w" T: Q" f+ c. w
Tumor Biology 6 {2 B2 Z$ ~7 e% o/ n/ V0 ~: j6 |# |
" h/ S' k9 `+ R
( W. d9 X/ I; h f" R5 u2 O) z* sMeeting:
+ | b: H8 s; W0 k5 \, @2011 ASCO Annual Meeting 3 O2 ]! W7 @9 x8 U
3 u+ L8 h& W6 s+ N
% j+ h5 T/ ?" U* g' S# ]
Session Type and Session Title:. V" E. P) }- S$ }6 A7 y6 W; r5 _
Poster Discussion Session, Tumor Biology 3 R7 g5 P" o i5 \1 {
4 A7 ?6 O- G* r0 @) A& ^/ \) U- o- ~9 u
Abstract No:
5 d4 o- t- z& n10517 % G, S7 Q" }8 Q$ d, o
) t$ `& D* r5 e, j& i7 h( r4 `+ k+ X1 c" K" i
Citation:2 c/ w! N& s/ G8 w% F9 q3 Q. J6 O
J Clin Oncol 29: 2011 (suppl; abstr 10517)
* S2 ?# h/ }/ W5 k3 Q# k( n" Z8 @2 p& V$ ]# g
# Q. ~ y9 W/ D# n: l, NAuthor(s):) {6 Y. Z% V+ g
J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
) P# z7 U- [) z q1 T0 @, S8 \
, T, U/ n, S& ]( l0 X2 n8 w
6 W$ C+ M! g; G C! D/ Z0 O* n- Y$ @6 `( M% O8 d
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
* L0 X1 X2 D. Q, w& U6 W
& ]* M' x5 K# ^2 f' tAbstract Disclosures
( a8 q, }! }0 H
$ g4 y& R9 }6 f/ l f7 wAbstract:* X @: i' J' j8 @7 R7 ~
8 N, F$ u. _, P- s, Z
. {& E m: N5 Z0 Z( c: C$ m" hBackground: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation., g# Y; l E2 z7 s5 R& V7 q
1 m/ O- ?% }; ~/ O% c# W; \ 1 y" e( a* b- O5 t, h2 a( n
|
显身卡
